Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20100524004010N39
IRCT20100524004010N39
Recruiting
Phase 2

The effect of co-administration of Dietary Approaches To Stop Hypertension (DASH) and Intermittent Fasting (IF) diets on hepatic parameters, glucose homeostasis, lipid profile and inflammatory biomarkers in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): a Randomized Control Trial

Shahid Beheshti University of Medical Sciences0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-alcoholic fatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
on-alcoholic fatty liver.
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
50
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Age over 18 years
  • •Having evidence of non\-alcoholic fatty liver in fibroscan (CAP score\>260\)
  • •Not having a history of alcohol consumption or alcohol consumption less than 10 grams per day in women and less than 20 grams per day in men.
  • •Not taking drugs that affect blood lipids, metformin, vitamin E and ursodeoxycholic acid (UDCA) and hepatotoxic drugs such as phenytoin, amoxifen and lithium.
  • •Not having chronic and acute liver diseases (hepatitis B, C, etc.), biliary disease, known autoimmune diseases, cancer and hereditary disorders affecting the liver (iron, copper storage disease)
  • •No history of weight loss surgery, weight loss program in the last 3 months
  • •Non\-adherence to special diets such as vegetarianism
  • •No history of uncontrolled thyroid disease
  • •Willingness to participate in the studuy
  • •Not having uncontrolled celiac disease, diabetes, cardiovascular disease, lung disease and kidney disease

Exclusion Criteria

  • •History of weight loss surgery and weight loss program during the last 3 months
  • •Failure to accept study conditions
  • •Taking medicine or supplements that can affect the results
  • •Following special diets and vegetarianism during the last 3 months
  • •Pregnancy or breastfeeding in women or Using birth control pills

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Assessing effectiveness of Weight loss and Exercise programs for older adults with Sarcopenic Obesity delivered via MobilE application/sSarcopenic ObesityMusculoskeletal - Other muscular and skeletal disordersDiet and Nutrition - Obesity
ACTRN12621000236897Deakin University116
Completed
Not Applicable
The effect of diet and CLA plus Omega-3 supplementation on aerobic and anaerobic performance, oxidative stress, body mass in endurance athletesAthletes.subpopulation Routine general health cheak-up of defined
IRCT201312223236N5Research Council of Shiraz University of Medical Sciences60
Recruiting
Not Applicable
Effect of dietary interventions based on Persian medicine on infantile gastroesophageal reflux.Infantile Gastroesophageal Reflux.Other specified perinatal digestive system disorders
IRCT20170701034828N1Vice chancellor for research, Shahed University84
Completed
Not Applicable
The effect of branched chain amino acids and vitamin B6 on weight lossCondition 1: obesity. Condition 2: overweight.Obesity due to excess caloriesObesity, unspecified
IRCT2016042813678N12Vice Chancellor for research of Urmia University of Medical Sciences42
Completed
Not Applicable
Effect of concomitant use of formula diet with dapagliflozin on body compositions, metabolic improvement, and its safety in type 2 diabetes mellitus.
JPRN-UMIN000024580onprofit Organization Hokkaido Health-Science Institute132